PHARMACY

Novartis, Amgen team on migraine, Alzheimer’s drug development

BY David Salazar

BASEL, Switzerland — Novartis and Amgen are joining forces to develop and commercialize neuroscience treatments in both their pipelines the companies announced Tuesday. The collaboration will see them working on a BACE inhibitor program to treat Alzheimer’s disease and developing Amgen’s migraine drugs.

"This Novartis collaboration with Amgen highlights our clear commitment to neuroscience and to bring multiple, new targeted therapies to patients living with Alzheimer's disease and migraine, where the unmet medical need remains high." Novartis Pharmaceuticals head David Epstein said.

The Amgen partnership comes on the heels of Novartis’ recent acquisition of Spinifex Phamceuticals, which added a compound for neuropathic pain to the company’s portfolio, and its agreement to acquire multiple sclerosis treatment Ofatumumab from GlaxoSmithKline. 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

QS1 offers myDataMart through FDS partnership

BY David Salazar

SPARTANBURG, S.C. — QS1 announced Wednesday that it would be partnering with business solutions company FDS to brings its customers FDS’s business intelligence software myDataMart. Using myDataMart, pharmacy owners can receive detailed analytics into the state of their business operations and potentially increase their Centers for Medicare and Medicaid Services Star ratings, QS1 said. 
 
“We are pleased to partner with FDS, a company that understands our commitment to offering the most advanced technology for our customers to efficiently run their businesses,” QS1 senior manger of marketing and analytics, Michael Ziegler, said.
 
myDataMart can be combined with QS1’s other dashboards and graphical support that the company said can aid in monitoring adherence among patients, Star rating measures and dispensing analysis. 
 
“QS/1 is always looking for ways to help our pharmacy customers succeed,” Ziegler added. “Improving adherence and Five-Star Quality Ratings will be an integral part of long-term success and growth. This partnership will build upon the resources already offered by QS/1.” 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Sandoz introduces rivastigmine patch

BY Lesley Thulin

PRINCETON, N.J. — Sandoz on Wednesday introduced rivastigmine transdermal system, a generic version of Exelon Patch1, in the United States.

The rivastigmine patch is used to treat mild, moderate and severe memory problems associated with both Alzheimer’s disease and Parkinson’s disease.

"Sandoz is pleased to make rivastigmine patch available as a generic option for patients with memory problems associated with Alzheimer’s disease,” Sandoz president Peter Goldschmidt said. “Rivastigmine has been studied for more than a decade in clinical trials and is the only Alzheimer's disease treatment that comes in the form of a patch with the medication absorbed through the skin.”

For the 12 months ending in June, U.S. sales for the rivastigmine patch were $646 million, according to the company. Sandoz will sell rivastigmine in 13.3 mg strength, the same strength as the brand.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?